S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:ESRX

Express Scripts (ESRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$92.11
$95.87
50-Day Range
$92.33
$92.33
52-Week Range
$66.93
$101.73
Volume
31.61 million shs
Average Volume
6.64 million shs
Market Capitalization
$52.06 billion
P/E Ratio
13.00
Dividend Yield
N/A
Price Target
N/A
ESRX stock logo

About Express Scripts Stock (NASDAQ:ESRX)

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.

ESRX Stock News Headlines

Scripts of success
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Amazon Pharmacy Fights For Recognition
The Future Of Drugstore Retailing
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Express Scripts Stages a Small Comeback
Express Scripts Inc
Express Scripts, Inc.
Express Coupons September 2022
See More Headlines
Receive ESRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Express Scripts and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2018
Today
4/17/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Stores & Proprietary Stores
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:ESRX
CUSIP
30219G10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$4.52 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$100.06 billion
Cash Flow
$10.49 per share
Book Value
$32.00 per share

Miscellaneous

Free Float
N/A
Market Cap
$52.06 billion
Optionable
Optionable
Beta
0.88
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Should I Buy Express Scripts Stock? ESRX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Express Scripts Holding:

  • Express Scripts Holding has a strong presence in the pharmacy benefit management (PBM) industry in the United States and Canada, offering a wide range of services including clinical solutions, specialty pharmacy care, and benefit design consultation.
  • The company's focus on providing affordable access to medication through programs like Inside Rx can attract a larger customer base, potentially leading to increased revenue.
  • Express Scripts Holding's diverse portfolio of services, including medical benefit management solutions for various healthcare areas, positions it well to capitalize on the evolving healthcare landscape.
  • Recent positive developments, such as Express Scripts beating earnings expectations, indicate potential growth and stability in the company's performance, which could be appealing to investors.
  • Considering the current stock price and market trends, investing in Express Scripts Holding may present an opportunity for capital appreciation in the near future.

Cons

Investors should be bearish about investing in Express Scripts Holding for these reasons:

  • Despite recent positive developments, the competitive nature of the PBM industry and potential regulatory changes could pose challenges to Express Scripts Holding's growth and profitability.
  • Fluctuations in healthcare policies and reimbursement rates could impact the company's financial performance and create uncertainty for investors.
  • Express Scripts Holding's reliance on government health programs and insurance providers exposes it to risks associated with changes in healthcare policies and regulations.
  • Investors should carefully monitor the company's ability to adapt to technological advancements and changing consumer preferences in the healthcare sector to ensure sustained growth and relevance.
  • While the company has a strong market presence, investors should consider the potential impact of any future mergers, acquisitions, or strategic shifts in the industry on Express Scripts Holding's competitive position and financial outlook.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Express Scripts pros and cons to contact@marketbeat.com.

ESRX Stock Analysis - Frequently Asked Questions

How were Express Scripts' earnings last quarter?

Express Scripts Holding (NASDAQ:ESRX) issued its earnings results on Wednesday, October, 31st. The company reported $2.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.42 by $0.01. The business had revenue of $25.56 billion for the quarter, compared to analysts' expectations of $25.11 billion. Express Scripts had a trailing twelve-month return on equity of 25.43% and a net margin of 4.83%. The company's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.51 EPS.

What other stocks do shareholders of Express Scripts own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Express Scripts investors own include Gilead Sciences (GILD), Bank of America (BAC), Cisco Systems (CSCO), General Electric (GE), Intel (INTC), Walt Disney (DIS), CVS Health (CVS), Boeing (BA), Starbucks (SBUX) and Johnson & Johnson (JNJ).

This page (NASDAQ:ESRX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners